ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Ramucirumab

Also written as “IMC-1121B (ramucirumab)”, “Ramucirumab (IMC-1121B)” and “IMC-1121B”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Neoplasms · Carcinoma, Hepatocellular · Breast Neoplasms, led by 6 companies.

Drug pageRamucirumab: every studyMany companies study it; this page follows only the 58 they lead. All 109 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Jun 20, 200858 company-led studies, 5 open or runningNext primary completion: May 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lillyits history only533 open or runningphase 3since Jun 20, 2008Aug 13, 2007May 2027phase 2 · NCT05999994
Arog Pharmaceuticalsits history only10 open or runningphase 1since Jun 14, 2017Jun 14, 2017none ahead
AstraZenecaits history only11 open or runningphase 2since May 5, 2025May 5, 2025Feb 23, 2029phase 2 · NCT06996782
Innovent Biologics10 open or runningphase 3since Dec 3, 2020Dec 3, 2020none ahead
Merckits history only11 open or runningphase 2since May 31, 2024May 31, 2024May 9, 2028phase 2 · NCT06445972
Sino Biopharmaceuticalits history only10 open or runningphase 1since Mar 24, 2023Mar 24, 2023none ahead

Also a collaborator on its studies: Daiichi Sankyo and Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Innovent Biologics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 3, 2020First study: phase 3 study in Gastric AdenocarcinomaFirst studyNCT04675983 · 36 enrolled · China

TargetBeta

KDR →read by rule
“A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity”NCIt, by rule
“Vascular endothelial growth factor receptor 2 inhibitor”ChEMBL 37, by rule

Other programs on KDR

ProgramCompanyFurthest phaseStudies
lenvatinibruleEisaiphase 481
nintedanibruleBoehringer Ingelheimphase 476
regorafenibruleBayerphase 440
cabozantinibruleExelixisphase 436
apatinibruleJiangsu HengRui Medicinephase 347
AxitinibrulePfizerphase 345
anlotinibruleSino Biopharmaceuticalphase 340
vorolanibruleBetta Pharmaceuticalsphase 324
zanzalintinibruleExelixisphase 317
chiauranibruleChipscreen Biosciencesphase 315
Aurora B/VEGFR/FGFR Inhibitor AL8326ruleadvenchen-laboratories-nanjing-ltdphase 38
AXL/FLT3/VEGFR2 Inhibitor KC1036rulebeijing-konruns-pharmaceutical-co-ltdphase 37

Studies

The one study Innovent Biologics leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04675983Gastric Adenocarcinoma · China3TerminatedFeb 12, 202336

How it is read

Names in the registry

  • “Ramucirumab”, 36 entries
  • “IMC-1121B (ramucirumab)”, 4 entries
  • “Ramucirumab (IMC-1121B)”, 4 entries
  • “IMC-1121B”, 4 entries
  • “ramucirumab (IMC-1121B)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.